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ABSTRACT
The urokinase plasminogen activator (uPA) receptor (uPAR)
is a GPI-linked cell surface protein that facilitates focused
plasmin proteolytic activity at the cell surface. uPAR has
been detected in macrophages inﬁltrating the central nerv-
ous system (CNS) and soluble uPAR has been detected in
the cerebrospinal ﬂuid during a number of CNS patholo-
gies. However, its expression by resident microglial cells
in vivo remains uncertain. In this work, we aimed to eluci-
date the murine CNS expression of uPAR and uPA as well
as that of tissue plasminogen activator and plasminogen ac-
tivator inhibitor 1 (PAI-1) during insults generating distinct
and well-characterized inﬂammatory responses; acute intra-
cerebral lipopolysaccharide (LPS), acute kainate-induced
neurodegeneration, and chronic neurodegeneration induced
by prion disease inoculation. All three insults induced
marked expression of uPAR at both mRNA and protein
level compared to controls (na€ ıve, saline, or control
inoculum-injected). uPAR expression was microglial in all
cases. Conversely, uPA transcription and activity was only
markedly increased during chronic neurodegeneration.
Dissociation of uPA and uPAR levels in acute challenges is
suggestive of additional proteolysis-independent roles for
uPAR. PAI-1 was most highly expressed upon LPS chal-
lenge, whereas tissue plasminogen activator mRNA was
constitutively present and less responsive to all insults
studied. These data are novel and suggest much wider
involvement of the uPAR/uPA system in CNS function and
pathology than previously supposed. V V C 2009 Wiley-Liss, Inc.
INTRODUCTION
The urokinase plasminogen activator (uPA) receptor
(uPAR) is a GPI-linked cell-surface protein that is best
characterized as a region-speciﬁc focus for uPA protease
activity at the cell surface. Binding of uPA to uPAR
greatly accelerates the cleavage of plasminogen to active
plasmin, and the receptor acts to concentrate this acti-
vation at discrete membrane locations. This is believed
to be a key event in cell adhesion and migration and has
been extensively researched in cancer metastases [see
(Blasi and Carmeliet, 2002) for review]. Monocytes/mac-
rophages are important migratory cells and uPAR has
been shown to be expressed by cells of the monocyte
lineage (Min et al., 1992; Vassalli et al., 1992) and to be
inducible by cytokines, in particular, transforming
growth factor b1 (TGFb1) (Lund et al., 1991). Under
normal conditions, uPAR expression is negligible and
uPAR knockout mice were initially found to be pheno-
typically normal but further study revealed that, under
challenge, they displayed defective recruitment and
migration of neutrophils and lymphocytes (Gyetko et al.,
2000, 2004). Low-level expression of uPAR has been
shown in cultured microglial cells, and this expression
was increased upon lipopolysaccharide (LPS) stimula-
tion; however, uPAR could not be detected in microglia
immediately ex vivo (Washington et al., 1996). Soluble
uPAR (suPAR) is elevated in the cerebrospinal ﬂuid
(CSF) of patients with HIV dementia (Cinque et al.,
2004), and it seems likely that this release of suPAR
into the CSF is directly related to increased central
nervous system (CNS) inﬂammation: uPAR has been
described in macrophages/microglia within the CNS in
traumatic brain injury, HIV dementia, multiple sclero-
sis, cerebral malaria, Creutzfeldt–Jakob disease (CJD),
and Alzheimer’s disease (Beschorner et al., 2000; Cinque
et al., 2004; Deininger et al., 2002; Fauser et al., 2000;
Gveric et al., 2001; Sidenius et al., 2004; Walker et al.,
2002). However, clear direct evidence for resident (i.e.
noninﬁltrating) microglial expression of uPAR is still
lacking, and its expression in different CNS insults has
not been studied in any systematic way.
It has been recognized for some time that tissue
plasminogen activator (tPA) is expressed and is constitu-
tively active in the normal CNS (Sappino et al., 1993),
in which it is proposed to have roles in synaptic plastic-
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V V C 2009 Wiley-Liss, Inc.ity, long-term potentiation, and neuronal migration [see
Melchor and Strickland (2005) for review]. In addition,
tPA activity is decreased in models of Alzheimer’s dis-
ease, and this is thought to occur through increased
expression of PAI-1 (Cacquevel et al., 2007; Melchor
et al., 2003). Conversely, tPA activity is increased upon
intracerebral injection of kainic acid, and this plasmin
activity has a key role in the resulting neurotoxicity
(Tsirka et al., 1995, 1997). Increased tPA activity in
models of prion disease have lead to the suggestion that
frustrated attempts by plasmin to proteolytically cleave
the deposited form of the prion protein result in
bystander damage to neuronal elements during this dis-
ease (Ellis et al., 2002; Maissen et al., 2001). However,
studies with tPA2/2 and plasminogen2/2 mice have
yielded contradictory results (Salmona et al., 2005;
Xanthopoulos et al., 2005). It is clear that tPA has multi-
ple roles in both physiological and pathological situa-
tions in the brain. Conversely, uPA has generally been
described as being absent from the normal CNS (Sap-
pino et al., 1993). However, uPA is known to be stress
responsive and is robustly induced during inﬂammation
(Gabay and Kushner, 1999). uPA is expressed in the
inﬂamed CNS in a model of experimental allergic ence-
phalopathy (East et al., 2005) and in cerebral ischemia
in rodents and in humans (Rosenberg et al., 1996).
Because it is clear that there is complimentarity and
redundancy in the plasmin cascade (Carmeliet et al.,
1994), it is important to study, in detail, the expression
of constituents of this system in vivo in addition to
deleting selected genes. We have studied the expression
of uPAR and uPA, as well as tPA and PAI-1, in the CNS
in a number of insults that generate distinct and well-
characterized inﬂammatory responses: acute nondege-
nerative inﬂammation induced by LPS (Andersson et al.,
1992), acute neurodegeneration-associated inﬂammation
induced by kainic acid (Andersson et al., 1991a,b), and
chronic neurodegeneration-associated inﬂammation
induced during prion disease (Betmouni et al., 1996;
Cunningham et al., 2002; Walsh et al., 2001). Together,
these insults generate a range of different innate inﬂam-
matory milieu in which uPAR and other components of
the plasmin cascade may be expressed in the brain.
These different insults induced alterations in the expres-
sion/activity of tPA and PAI-1 that were consistent with
previous observations, but also revealed novel patterns
of uPA and uPAR expression that suggest wider
involvement of this system in the CNS than previously
supposed.
EXPERIMENTAL
Animals and Stereotaxic Surgery
Female C57BL/6 mice were obtained from Harlan
(Bicester, UK), housed in groups of ﬁve or six under
standard light and temperature regimes, and fed with
pelleted food and water ad libitum. For LPS challenges,
animals were anesthetized with intraperitoneal avertin,
positioned in a stereotaxic frame, and injected with
2.5 lg LPS (Salmonella equine abortus, Sigma, Poole,
UK) in 1 lL, via a pulled glass microcapillary tube
(coordinates from bregma: anterior–posterior 22.0 mm,
lateral 21.6 mm, and depth 21.5 mm). For kainate chal-
lenges, 1 nmol of kainic acid (Sigma, Dorset, UK) was
injected by exactly the same method as used for LPS.
For inoculation with prion disease, animals were anes-
thetized in the same manner, and 1 lL of a 10% w/v
ME7-infected C57BL/6 brain homogenate, made in phos-
phate-buffered saline (PBS), was injected bilaterally into
the dorsal hippocampus (same coordinates) via a 10-lL
Hamilton syringe. Control animals were injected with a
10% w/v normal brain homogenate (NBH) in PBS,
derived from a naive C57BL/6 mouse. In addition, we
made saline challenges and collected tissue from naive
mice, both young adult and 8–9 months (age-matched to
late stage ME7 and NBH animals). All procedures were
carried out in accordance with UK Home Ofﬁce license.
Tissue Preparation
Animals challenged intracerebrally with LPS were ter-
minally anesthetized at 6, 8, or 72 h post-LPS and
examined for evidence of cell inﬁltration/inﬂammatory
activation, because cytokine expression/microglial acti-
vation occurs signiﬁcantly earlier (6/8 h) than macro-
phage and neutrophil inﬁltration (Andersson et al.,
1992). Kainate-injected animals were euthanised at 24 h
or 72 h post-injection. Neurodegeneration begins syn-
chronously upon kainate challenge but signiﬁcant mac-
rophage inﬁltration occurs at 48 h post-kainate (Anders-
son et al., 1991a) and at 72 h most of the CA1 neurons
of the hippocampus show clear morphological signs of
nuclear condensation. Animals inoculated with ME7
prion disease were euthanized at 12, 15, 18, 20, and 23
weeks postinoculation for all mRNA studies, with NBH
animals taken at 12 and 23 weeks for comparison. For
protein expression studies in the ME7 model, this range
was narrowed to 13, 18, and 21 weeks postinoculation to
reduce animal usage. These times represent points in dis-
ease displaying hippocampal synaptic loss, hippocampal
neuronal cell soma loss, and terminal disease, respec-
tively (Cunningham et al., 2003a). Tissues were homoge-
nized in PBS with Complete
TM protease inhibitor cocktail
(Roche) and centrifuged at 12,000 rpm for 10 min, and the
supernatant was harvested (S1, representing soluble pro-
teins). The pellet was then solubilized by incubation
with1% triton-X100 for 1 h at 4C and recentrifuged at
12,000 rpm for 10 min (P1, representing membrane-asso-
ciated proteins).
All animals used for RNA extraction were terminally
anesthetized using sodium pentobarbital, transcardially
perfused with heparinized saline, and the brains
removed (n 5 5 for each animal group). Thick coronal
sections ( 2 mm) were taken at  21.0 to 23.0 mm from
Bregma, and the hippocampus and dorsal thalamus
were quickly removed, immediately frozen in liquid
nitrogen, and stored at 280C.
1803 MICROGLIA AND THE uPAR/uPA SYSTEM
GLIAAnimal groups for immunohistochemistry were termi-
nally anesthetized and transcardially perfused with hep-
arinized saline and ﬁxed in 10% formalin solution (n 5
3 for ME7, LPS, KA). Additional groups were perfused
with freshly prepared paraformaldehyde-lysine-period-
ate ﬁxative (PLP; 2% paraformaldehyde, 0.05% glutaral-
dehyde, 70 mM lysine, and 10 mM sodium periodate) to
preserve the cell-surface markers uPAR and F4/80 (n 5
3 for ME7, LPS, KA).
RNA Extraction
Total RNA was extracted from brain samples using
Qiagen RNeasy mini columns (Qiagen, Crawley, UK)
according to the manufacturer’s instructions. Contami-
nating genomic DNA was degraded during extraction
with Qiagen DNase1 enzyme. The typical yield for brain
tissue was  5 lg per extraction. RNA was stored at
280C until cDNA synthesis and PCR assay. Group
sizes for mRNA extraction were as follows: NBH (n 5
6), na€ ıve, aged and 18-week ME7 (n 5 4), 23-week ME7
(n 5 5), and all others (n 5 3).
Taqman RT-PCR Assay
All equipment and reagents were supplied by Applied
Biosystems (Warrington, UK) unless otherwise stated.
Assays for PAI-1 and tPA were designed using the pub-
lished sequences for these genes, applied to Primer
Express software. Primer and probe sequences for uPA
and uPAR were kindly supplied by Prof. Dylan Edwards.
The sequences are shown in Table 1. Where possible,
probes were designed to cross an intron to ensure that
they were cDNA speciﬁc. Table 1 lists the sequences for
primers and probes for each assay. All primer pairs were
checked for speciﬁcity by standard RT-PCR using Prom-
ega PCR reagents (Southampton, UK) followed by gel
electrophoresis. Each primer pair produced a discrete
band of the expected amplicon size (not shown).
For Taqman PCR, cDNA was generated from total
RNA using Taqman Gold RT reagents. Two hundred
nanograms of total RNA were reverse transcribed in a
10-lL reaction volume. One microliter of the RT reaction
(equivalent to 20-ng RNA) was subsequently used for
the PCR and performed as previously described (Cun-
ningham et al., 2005). A standard curve was constructed
from total RNA isolated from mouse brain tissue after
intracerebral challenge with 2.5 lg LPS, which is known
to upregulate all target transcripts of interest in this
study. This standard curve was constructed using a
higher concentration of RNA in the reverse transcrip-
tase reaction than for samples for analysis to ensure
that transcription in all animal groups would fall within
the range of the standard curve constructed. Serial 1 in
ﬁve dilutions of the cDNA synthesized from brains of
LPS-injected mice were made and a curve plotted of the
Ct value (the cycle number at which the transcribed
gene crosses the threshold of detection) versus the log of
the concentration (assigned an arbitrary value since the
absolute concentration of cytokine transcripts is not
known). Thus, the standard curve generates arbitrary
values for concentration. These data were then normal-
ized for GAPDH concentration in each sample.
Western Immunoblotting
Pellet-enriched fractions were prepared as described
for P1 (see tissue preparation) from LPS, kainate, and
ME7 animals and analyzed for uPAR protein expression
by western blot. Brieﬂy, 25 lg of each lysate was loaded
and run under reducing conditions on a 10% SDS–PAGE
gel. Samples were transferred to PVDF, blocked in 5%
nonfat milk in PBS-T (PBS and 0.2% Tween-20) for 2 h,
and probed overnight with a polyclonal anti-mouse
uPAR antibody (anti-smuPAR) at 1 lg/mL. The antibod-
ies against uPAR, both polyclonal and monoclonal, were
produced using recombinant smuPAR expressed in
Schneider S2 cells using the Drosophila Expression
System Kit (Invitrogen) as antigen. The protein was
puriﬁed from the conditioned media of stably transfected
S2 cells using Ni-NTA beads (Qiagen) followed by gel
ﬁltration. Rabbits and uPAR
2/2 mice were immunized
with recombinant smuPAR, and the IgG fraction of rab-
bit serum and hybridoma conditioned media were subse-
quently afﬁnity puriﬁed on a column containing immobi-
lized smuPAR (Sidenius, unpublished work). Detection
was achieved with a 1:5,000 dilution of anti-rabbit-HRP
or anti-mouse-HRP (GE Healthcare) and development
with ECL reagent (PIERCE). The appropriate uPAR
detection and speciﬁcity of this antibody were veriﬁed
by transfection of Chinese Hamster Ovary cells with
murine uPAR (Supp. Info. Fig. 1) and by staining of
kidney tissue from wild type and uPAR2/2 mice (Tjwa
et al., 2009).
Plasminogen Activation Assay
Samples were analyzed for plasminogen activation
activity in an indirect enzymatic assay in a 96-well for-
mat using the chromogenic plasmin substrate Chromo-
zym PL (Roche) with output at 410 nm. Reactions were
carried out in assay buffer (50 mM Tris–HCl, pH 7.4,
100 mM NaCl) containing a ﬁnal concentration of 0.2
lM plasminogen (Sigma), 0.2 mM chromozym PL, and
50-lg protein extract. Where a distinction between tPA
and uPA activity was desired, selective inhibitors of
each of the plasminogen activators were used. For tPA
inhibition, a commerical tPA inhibitor, tPA Stop (Amer-
ican Diagnostica, Stamford, CT), was included in the
reaction mix at a ﬁnal concentration of 1.5 lM. uPA was
inhibited using amiloride (Sigma) at a ﬁnal concentra-
tion of 0.2 mM. Although these inhibitors are not
entirely speciﬁc, they do show good selectivity at the
concentrations used: 0.2 mM amiloride signiﬁcantly
inhibits uPA while having a minimal effect on tPA activ-
ity while the Ki of tPA STOP is 0.035 lM for tPA and
1804 CUNNINGHAM ET AL.
GLIA3.4 lM for uPA (Harvey and Chintala, 2007). Samples
were allowed to run overnight at room temperature, and
data were collected using a DYNEX MRX plate reader
using Revelation software (Worthing, UK).
Gel zymography for tPA and uPA Activity
Enzyme activities for tPA and uPA were assessed
using gel zymography. A substrate solution of 8% w/v
Marvel dry milk in PBS, containing CaCl2 (0.9 mM) and
MgCl2 (1.0 mM), was prepared. A 10% SDS2PAGE gel
was prepared with 400 lL of 8% milk solution per
20 mL of resolving gel. In addition, 133 lL of plasmino-
gen (1.5 mg/mL; Sigma P-7397) was added to the resolv-
ing gel. Solubilized pellets and supernatants (15-lg
protein per lane) were added to loading buffer without
mercaptoethanol and were not boiled before loading on
the gel. Gels were run at 25 mA per minigel. The gels
were rinsed in 2.5% Triton X-100 and then incubated in
10 mM CaCl2, 50 mM Tris (pH 7.6) for 6 h at 37C.
After this time, the gel was rinsed again and stained in
Coomassie blue for 1 h before destaining until areas of
proteolysis became apparent as clear areas in the
intense blue staining of the remaining casein protein
throughout the gel.
Immunohistochemistry for uPAR and F4/80
Immunohistochemistry was carried out for uPAR and
F4/80. All biotinylated secondary antibodies were sup-
plied by Vector laboratories (Peterborough, UK) and all
staining was visualised using the ABC method using
peroxidase as enzyme, 0.015% v/v hydrogen peroxide as
substrate and diaminobenzidine as chromagen. Frozen
paraformaldehyde-lysine-periodate-ﬁxed brain sections
were cut on a cryostat and stored at 220C. On removal
from the freezer sections were dried at 37C for 30 min.
Endogenous peroxidase was quenched using methanol
containing 1 ml 30% H2O2 for 20 min. Sections were
washed with PBS-Tween (0.1%) and blocked using both
Vector Avidin-Biotin block and Mouse-On-Mouse (MOM)
blocking reagents. After 1 h of blocking with MOM
blocking diluent and 5 min with MOM working solution,
the primary monoclonal antibody BR4.8 (Sidenius,
unpublished) was applied at 2 lg/ml and left to incubate
in a humidiﬁed chamber for 2 h. This antibody was then
washed off and sections were washed overnight in PBS-
Tween. Biotinylated horse anti-mouse antibody was pre-
pared in MOM diluent and left at room temperature for
30 min. ABC incubation and DAB staining were then
performed as normal. Sections for F4/80 staining were
oven dried and washed as before and then blocked for
30 min with normal 10% rabbit serum before incubation
with the F4/80 antibody (Serotec, Oxford, UK) for 1 h at
room temperature. The sections were then washed and
incubated with biotinylated rabbit anti-rat antibody for
45 min and continued through ABC incubation and
DAB/peroxidase reaction as before.
Statistical Analysis
Gene expression data were analyzed by comparing all
‘‘acute’’ groups (na€ ıve, saline, LPS, and KA) or all
‘‘chronic’’ groups (NBH, 12 weeks, 15 weeks, 18 weeks,
20 weeks, 23 weeks, and age-matched naive) by one-way
ANOVA followed by selected pair-wise comparisons by
Bonferroni post hoc tests. Signiﬁcance was accepted at
the 95% conﬁdence interval.
RESULTS
Transcriptional Regulation of PA Components
during CNS Inﬂammation
After RNA isolation from brain homogenates of
treated mice, cDNA was synthesized and examined for
transcription of uPAR, uPA, tPA, and PAI-1.
Transcription of uPAR was markedly increased for all
challenges compared to their relevant control groups
(Fig. 1a). LPS induced a 41-fold increase with respect to
na€ ıve animals and a 15-fold increase with respect to
saline-injected animals (P < 0.001). KA induced a 50-
fold increase with respect to na€ ıve and an 18-fold
increase with respect to saline-injected animals (P <
0.001). Injection of saline alone increased uPAR expres-
sion with respect to na€ ıve animals. This was not statisti-
cally signiﬁcant when all acute groups were compared,
TABLE 1. Sequences of Primers and Probes Used in Quantitative TaqMan Analyses
Target Oligonucleotide Sequence Amplicon size (bp)
tPA Forward primer 50-GGCCTGGCACGACACAAT-30 66
Reverse primer 50-CATCACATGGCACCAAGGTC-30
Probe 50-ATTGTCGGAATCCAGATGGTGATGCC-30
PAI-1 Forward primer 50-GGGACACCCTCAGCATGTTC-30 69
Reverse primer 50-TGTTGGTGAGGGCGGAGA-30
Probe 50-TCGCTGCACCCTTTGAGAAAGATGT-30
uPA Forward primer 50-GAAACCCTACAATGCCCACAGA-30 127
Reverse primer 50-GACAAACTGCCTTAGGCCAATC-30
Probe 50-CACAATTACTGCAGGAACCCTGACAAC-30
uPAR Forward primer 50-TGCAATGCCGCTATCCTACA-30 116
Reverse primer 50-TGGGCATCCGGGAAGACT-30
Probe 50-CCCTCCAGAGCACAGAAAGGAGCTTGAA-30
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groups, this difference is readily apparent (P < 0.001).
To investigate expression in chronic inﬂammation, we
compared ME7 prion-diseased animals with NBH
controls. NBH animals at 23 weeks postinoculation
showed low-uPAR levels, similar to both aged-matched
and young na€ ıve animals (not signiﬁcantly different by
ANOVA with Bonferroni post hoc test). In contrast, ME7
animals showed a clear and time-dependent increase in
expression of uPAR with disease progression, reaching
 15-fold elevation compared to NBH animals by 20
weeks postinoculation. This increase is apparent by 12
weeks and statistically signiﬁcant by 15 weeks (ANOVA
with Bonferroni post hoc P < 0.001).
The mRNA for the protease uPA shows only variable
and limited induction by LPS at 24 h or kainate at 72 h
(Fig. 1b), and these increases are not statistically signiﬁ-
cant at these time points (no main effect by one-way
ANOVA, no post hoc tests performed). In ME7 animals,
by contrast, uPA transcription was markedly induced,
by  17-fold by 20 weeks postinoculation. This increase
is once again time-dependent, with induction already
apparent and statistically signiﬁcant at 12 weeks
(Bonferroni post hoc P < 0.01). There were no signiﬁcant
differences between saline-injected, NBH-injected, or
young or older na€ ıve mice.
tPA is constitutively expressed in the brain and
mRNA expression levels accordingly appear high at
baseline and are less inducible (Fig. 1c). LPS challenge
induced a moderate increase in expression with respect
to na€ ıve (P < 0.001) and to saline-treated animals (P <
0.01), but saline also induced a modest, though nonsigni-
ﬁcant increase with respect to na€ ıve animals (P > 0.05).
tPA expression was induced in KA-injected animals (P <
0.01 versus na€ ıve animals), but the induction was highly
variable, and this increase did not reach statistical sig-
niﬁcance with respect to saline-treated animals. There is
also a trend toward a time-dependent increase in tPA
expression during prion disease progression, but even at
peak expression, levels are only increased approximately
twofold with respect to NBH controls and this does not
reach statistical signiﬁcance.
PAI-1 expression (Fig. 1d) was markedly induced by
LPS compared to levels of expression in saline-treated ani-
mals (P < 0.001). PAI-1 was also induced in KA-injected
animals but only to a modest and highly variable degree
(nonsigniﬁcant, P > 0.05). PAI-1 was clearly induced with
the progression of prion disease. This increase did not
Fig. 1. Quantitative PCR analysis of gene expression changes in
uPAR, uPA, tPA, and PAI-1. Total RNA was isolated from hippocampus
at various time points (LPS: 24 h, KA: 48 h, Saline, 24 h, and ME7 as
described on x-axis). Synthesized cDNA was analyzed using TAQMAN
PCR using speciﬁc primers and probes designed from published sequen-
ces for these genes. Statistical signiﬁcance was determined by ANOVA
with Bonferroni post hoc tests and P values are denoted by * (P <
0.001), **(P < 0.01), and ***(P < 0.05). Group sizes for mRNA extrac-
tion were as follows: NBH (n 5 6), nay ¨ve, aged and 18-week ME7 (n 5
4), 23-week ME7 (n 5 5), and all others (n 5 3).
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and by 23 weeks was elevated approximately sixfold.
uPAR Protein Expression During CNS
Inﬂammation
Hippocampal homogenates were prepared at 8 h and 3
days after intracerebral injection with LPS and from
animals 8 h after saline injection. Further homogenates
were prepared from kainate-injected hippocampi 24 and
72 h after challenge or 24 h after saline injection.
Homogenates from NBH animals (21 weeks) and ME7
animals (13, 18, and 21 weeks) were also prepared.
These times are justiﬁed in the Experimental section.
Homogenates were analyzed by PAGE and Western
blotting for uPAR protein levels using an anti-mouse
polyclonal antibody, and the results are summarized in
Figure 2a. Because of its marked glycosylation, previ-
ously observed in mice (Cunningham et al., 2003b) and
humans (Roldan et al., 1990), uPAR runs as a smear at
between 45 and 60 kDa. LPS induced a marked expres-
sion of uPAR protein at 8 h postinjection and a dramatic
increase by 3 days posttreatment (Fig. 2a). A further
band at  35 kDa may represent the unglycosylated
form of the protein (Roldan et al., 1990). Further data
(Supp. Info. Fig. 2) show that the pattern of uPAR
expression/glycosylation is not yet altered 2 h post-LPS,
but is altered at 6 h and markedly so at 24 h. Immuno-
blots with mouse anti-b-actin and with goat anti-rabbit
IgG on the same membrane veriﬁed that all lanes show
approximately equal loading and that the observed
bands are a consequence of binding of the rabbit
antimurine uPAR antibody. uPAR was expressed at very
low levels in saline-treated animals. Kainate-injected
animals also showed clear expression of uPAR at 24 h
postinjection with respect to saline-treated controls
(Fig. 2b). This expression appeared to decrease by 3
days. ME7 animals showed a time-dependent increase in
uPAR expression, with marked expression by 13 weeks
and continued increases at 18 and 21 weeks, respec-
tively (Fig. 2c). NBH controls showed no evidence of
uPAR expression in the brain.
Conﬁrmation of both tPA and uPA Expression
and Activity in the CNS
Because mRNA expression analysis indicated that
both uPA and tPA activities may be present in some of
the innate inﬂammatory responses under study, we
examined this possibility further using both gel zymog-
raphy and soluble assays in the presence of selective
inhibitors. In these experiments, brain homogenates
from progressive stages of prion disease were analyzed.
The gel zymography method separates tPA and uPA
activities on the basis of size, with tPA running at a
molecular weight of  67 kDa and uPA, in its pro form,
at  50 kDa. Figure 3a shows that uPA protein increases
in a time-dependent manner during the course of prion
disease, consistent with the mRNA data. Under the
same conditions, tPA protein expression is constitutively
high with less marked increases observed with disease
progression. In this case, the majority of tPA is associ-
ated with the soluble fraction. Figure 3b illustrates that
both uPA and tPA activities are present in membrane
fractions of the ME7 brain, with comparable fractions of
total plasminogen activation being inhibited by selective
tPA and uPA inhibitors [tPA stop (1.5 lm) and amiloride
(0.2 mM) respectively]. These inhibitors may also affect
the activity of plasminogen activators even when recep-
tor-bound, which may be signiﬁcant given the ability of
the plasminogen activators to act as soluble of receptor-
bound forms.
Plasminogen Activation During Distinct
CNS Pathologies
Gel zymography analysis showed the presence of both
uPA and tPA in the brain and associated increases
during the progression of prion disease. However,
zymography cannot assess the activities of these
enzymes in solution, because inhibitors such as PAI-1
may remain bound on the nonreducing gel. To assess
the effects of the three distinct CNS insults on total
plasminogen activation, activity was measured in total
brain homogenates as described earlier (those used for
zymography). Both soluble and membrane-associated
homogenate fractions were analyzed in each case. An
Fig. 2. Western blot analysis of uPAR expression in hippocampal
homogenates. Membrane fraction samples (25 lg protein) were
separated by SDS–PAGE, transferred to PVDF, immunoblotted with a
polyclonal antisoluble mouse uPAR antibody at 1 lg/mL and developed
with ECL. (a) LPS (8 or 72 h) or saline treatment (8 h) (n 5 3 for all
groups). (b) Kainate (24 or 72 h) and saline groups (24 h) (n 5 3 for
all groups). (c) ME7 (13, 18, and 21 weeks) and NBH (21 weeks) (n 5 4
for each group: one representative gel shown.).
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sion of prion disease is apparent in both soluble and
membrane fractions (Fig. 4a,b, respectively). This
increase is more apparent, and clearly time-dependent,
in PA associated with the membrane fraction. Similar
total PA increases are evident after kainate challenge
(Fig. 4c). However, total PA activity decreases after LPS
challenge (Fig. 4d). Only soluble fractions are shown for
kainate and LPS challenges as the trend is similar for
membrane-associated fractions in both cases.
Cellular Localization of uPAR in the CNS
Immunolabeling revealed that uPAR is expressed in
cells with typical, classical microglial morphologies
(Streit et al., 1999) in all three conditions and also in
inﬁltrating macrophages after LPS challenge. The stain-
ing levels are very low in saline-injected (Fig. 5a) and
NBH-injected control animals (Fig. 5c), but there was
nonetheless, labeling of the highly ramiﬁed processes of
microglial cells in their normal quiescent state (5 o,p).
The staining was clearly increased in animals 8-h post-
LPS challenge, and this staining revealed microglial
cells maintaining a ramiﬁed morphology (Fig. 5b).
Animals examined 3 days after LPS challenge showed
evidence of diffuse extracellular uPAR staining, appa-
rently throughout the parenchyma, consistent with
cleavage of GPI-linked uPAR to increase suPAR levels
(Fig. 5j). Cleavage and shedding of uPAR is well docu-
mented in monocytes (Sidenius et al., 2000). In the same
manner, uPAR was upregulated 3 days post-KA chal-
lenge on microglial cells with shortened processes in the
vicinity of the dying neurons of the CA1 (Fig. 5e,i,s,t).
Furthermore, the contralateral side to KA injection also
showed hyper-ramiﬁed microglial staining with uPAR
expression (Fig. 5d,q,r). ME7 animals also showed clear
evidence of microglial uPAR staining (Fig. 5f) with
microglia showing upregulation of uPAR throughout the
hippocampus and dorsal thalamus, as has been shown
previously for other microglial markers in this disease
model (Betmouni et al., 1996). Similar to LPS and KA
challenges, ME7 animals also showed evidence of diffuse
uPAR staining in the parenchyma that was not associ-
ated with particular cells (Fig. 5h) and was increased
relative to the very low-parenchymal labeling in NBH-
treated animals (Fig. 5c,g).
We also stained for F4/80 after the various challenges
used in this study to conﬁrm the morphology and loca-
tion of macrophages/microglia following these insults.
F4/80 immunostaining revealed constitutive labeling of
ramiﬁed microglial cells in NBH and saline-injected
animals (Fig. 5k,p), and this morphology was shared by
uPAR-positive cells (Fig. 5o). The levels of expression of
the F4/80 antigen and the morphology of macrophages/
microglia are altered in LPS, KA, and ME7-injected
animals (Fig. 5n,m,l, respectively). This is most obvious
ipsilateral to KA challenge, after which the microglial
processes become shorter and condensed, and these cells
invade the degenerating CA1 neuronal layer (Fig. 5m).
This classical activated/amoeboid morphology is clearly
shown by both uPAR and F4/80 (Fig. 5s,t). Signiﬁcantly,
the hyper-ramiﬁed morphology typical of ‘‘alert’’ micro-
glia was also observed on the contralateral side to the
kainate challenge and also is displayed by both markers
(Fig. 5q,r). Thus, F4/80-staining parallels the cellular
staining observed with the anti-uPAR antibody in its
morphology and localization after the different chal-
lenges. Signiﬁcantly, uPAR expression is present in
resident microglial cells before any inﬁltration of cells
from the bloodstream has taken place (Andersson et al.,
1992).
DISCUSSION
We have shown here that uPAR is expressed by resi-
dent microglial cells of the murine brain and that it is
signiﬁcantly upregulated in the brain in response to a
number of challenges that provoke an innate immune
response. At peak expression, there is considerable shed-
ding of this GPI-linked protein from the cell surface into
the brain parenchyma. This is the ﬁrst clear demonstra-
tion, in vivo, that resident microglia as well as inﬁltrat-
ing macrophages expresses this protein. In addition, we
Fig. 3. Zymographic and 96-well soluble assay of plasmin activity in
ME7 animals. (a) Plasmin activity was assessed in both soluble and
membrane fractions by in-gel zymography. The activity of both tPA and
uPA are visible on the gel at MWs of  67 and 50 kDa, respectively (pro
forms). Samples are in duplicate and one representative gel of two per-
formed (n 5 4) is shown. Images have been captured by digital camera
and reversed to increase the clarity of the banding pattern. (b) Plasmin
activity was assessed by 96 well assay using ChromazymPL as sub-
strate. Data represent the mean 6 SEM for n 5 4 in each experimental
group. Selective inhibition of plasmin activity at 18 weeks postinocula-
tion with ME7 prion disease using selective inhibitors of tPA (tPA stop,
1.5 lm) and uPA (amiloride, 0.2 mM) revealed the presence of both
activities in this membrane fraction.
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GLIAhave shown expression and activity of uPA in the
murine brain, particularly during the progression of
chronic neurodegeneration caused by the ME7 strain of
murine prion disease. There are interesting dissociations
between the inductions of uPA and uPAR among the
various challenges studied here. Both LPS and kainate-
induced neurodegeneration led to very marked induc-
tions of uPAR with minimal effect on uPA expression,
whereas chronic neurodegeneration induces uPA and
uPAR transcriptional increases of similar magnitude
(14–20-fold) perhaps indicating divergent roles of prote-
ase activity in these models.
uPAR and uPA Expression in the Brain
Monocytes/macrophages are known to express uPAR
(Min et al., 1992; Vassalli et al., 1992), and levels of
expression are reported to be elevated during endotox-
emia and by various cytokines including IL-1b, TNF-a,
and TGFb1 (Dekkers et al., 2000; Yue et al., 2004). The
expression of uPAR and its site-directed focusing of uPA
activity play a central role in cell migration and inﬁltra-
tion to sites of inﬂammation (Gyetko et al., 2000, 2004).
Low-level expression of uPAR has been described in
microglial cells in vitro, and this expression was
increased upon LPS stimulation; however, uPAR could
not be detected in microglia immediately ex vivo by
these authors (Washington et al., 1996). There have
been reports of brain macrophage/microglial cell surface
uPAR expression in HIV dementia, multiple sclerosis,
cerebral malaria, traumatic brain injury, CJD, and
Alzheimer’s disease (Beschorner et al., 2000; Cinque
et al., 2004; Deininger et al., 2002; Fauser et al., 2000;
Gveric et al., 2001; Sidenius et al., 2004; Walker et al.,
2002). Some of these studies show either double staining
with macrophage markers or morphology suggestive of
microglial cells. However, most of these studies describe
Fig. 4. Total plasmin activity in soluble and/or membrane fractions
of homogenates of hippocampal tissue from animals injected with NBH,
ME7, LPS, KA, or saline. (a) Soluble fractions of NBH and ME7 (13,
18, and 21 weeks). (b) Membrane fractions of NBH and ME7 (13, 18,
and 21 weeks). (c) Soluble fractions of KA (24 and 72 h) and saline-
injected (24 h). (d) Soluble fractions of LPS (8 and 72 h) and saline-
injected animals (8 h). Data represent the mean for n 5 4i ne a c h
experimental group. Error bars have been omitted for clarity, owing to
the frequency of sampling.
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GLIAconditions in which macrophages have recently inﬁl-
trated the brain. Even in a chronic disease, such as
Alzheimer’s disease (Walker et al., 2002), in which uPAR
positive staining is colocalized with CD68-positive
macrophages, it is not clear whether these are resident
or inﬁltrating cells, because bone marrow-derived
inﬁltrating macrophages have been reported to be selec-
tively targeted to amyloid plaques in animal models of
Alzheimer’s disease (Simard et al., 2006).
In this study, we demonstrate that uPAR is expressed
in resident microglial cells in the normal brain and in
both acute and chronic inﬂammation. Immunohisto-
Fig. 5. Cellular localization of uPAR expression. PLP-ﬁxed brain
sections were immunostained for uPAR (a–j) to identify the cellular
source of uPAR in the brain after various insults and for F4/80 (k–n)t o
conﬁrm morphology and location of macrophages/microglia following
these insults. Low-level staining of highly ramiﬁed microglial processes
can be observed in control animals; (a) saline (8 h) and (c) NBH (18
weeks). Increased expression is evident in (b) LPS (8 h) tissue and (d)
contralateral to KA challenge, though the morphology remains quite
ramiﬁed. Marked expression of uPAR is evident in amoeboid microglia
ipsilateral to KA challenge (e) and in condensed microglia in ME7-
treated animals (f). In addition to cellular staining, uPAR appears to be
released into the parenchyma after ME7 (h), KA (i), and LPS (j) chal-
lenges. The site of injection is indicated by *. F4/80 staining reveals
constitutive labelling of ramiﬁed microglial cells in NBH controls (k).
The levels of F4/80 and cell morphology are altered in ME7 (l), KA (m),
and LPS 3 days (n). uPAR and F4/80 are also shown at 1003 magniﬁ-
cation to illustrate the similar morphologies of the cells positively
labeled for these antigens (o–t). Both markers display the ramiﬁed
(saline: o, p), hyper-ramiﬁed (kainate contralateral: q, r) and activated/
amoeboid (kainate ipsilateral: s, t). Scale bars 5 70 lm (a–f), 1 mm
(g–j), 50 lm (k–n), and 10 lm (o–t).
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GLIAchemistry reveals that uPAR is expressed at very low
levels in na€ ıve and saline-treated mice but is signiﬁ-
cantly upregulated by LPS many hours before cell inﬁl-
tration occurs, demonstrating that resident microglial
cells upregulate this cell surface marker upon stimula-
tion. In light of its role in cell migration, the expression
of uPAR by inﬁltrating macrophages in the brain was
readily rationalized. Although the need for local extrac-
ellular protease activity is not so obvious for resident
cells, recent data demonstrate that microglia continually
explore their local microenvironment, and these cells are
well known to respond rapidly to transient neural activ-
ity suppression by stimulation with potassium chloride
(cortical spreading depression: (Gehrmann et al., 1993;
Jander et al., 2001) and to show activation in undam-
aged regions, distal to ischemic lesions (Schroeter et al.,
1999). In this regard, it is interesting that in our studies
even saline challenges produce measurable increases in
uPAR gene expression when compared with na€ ıve ani-
mals and that uPAR is robustly expressed in hyper-
ramiﬁed microglia contralateral to kainate challenges,
indicating that even minor disturbances to the brain
parenchyma provoke transcriptional, translational, and
perhaps structural changes in microglial cells. The inter-
action of uPA with uPAR may thus contribute to mor-
phological changes and migration toward relatively
proximal stimuli.
It is also possible that uPAR has roles in brain inﬂam-
mation that are entirely dissociated from the focusing of
uPA activity. We show here that uPAR is highly
expressed after both kainate and LPS challenges, but
that uPA is not signiﬁcantly upregulated under the
same conditions. There is now a large body of evidence
to support multiple proteolysis-independent roles for
uPAR in cell adhesion, migration, proliferation, and
differentiation outside the CNS [reviewed in Blasi and
Carmeliet (2002)]. Recent experiments suggest that
uPAR has a uPA-independent role in ischemic damage
(Nagai et al., 2008). A second, key-binding partner of
uPAR is the extracellular matrix protein vitronectin
(VN). Overexpression of uPAR in HEK-293 cells in vitro
and subsequent uPAR-VN interaction was shown to
induce profound changes in cell morphology, including
cell spreading and rearrangement of the actin cytoskele-
ton and focal adhesion contacts (Madsen et al., 2007).
This cell–matrix interaction could be postulated to medi-
ate the morphological changes that are observed upon
activation of resident microglia, leading to the less-rami-
ﬁed, more-condensed morphology after inﬂammatory
challenges. In addition, VN has been shown to be
present in diffuse and dense core plaques in Alzheimer’s
disease (Akiyama et al., 1991), and its interaction with
uPAR may also inﬂuence microglial activation at the
plaque periphery.
We also observed variation in uPAR glycosylation with
different challenges. Levels of uPAR protein expression
are most robustly induced after acute LPS challenge,
and it is also this condition that leads to the highest
level of uPAR glycosylation (Fig. 2a). In contrast, uPAR
glycosylation is not as marked during the development
of prion disease (Fig. 2c). Time-dependent changes in
uPAR glycosylation levels have previously been observed
during monocyte activation, and this has been shown to
be correlated with protein–protein interactions impor-
tant in mediating cell adhesion (Mahoney et al., 2001).
Similar alterations in N-glycosylation patterns have
recently been reported in a number of inﬂammatory
conditions including sepsis, acute pancreatitis, and sys-
temic lupus erythematosus (Gornik et al., 2007; Hashii
et al., 2008), and the signiﬁcance of different glycosyla-
tion patterns in the current data merits further study.
The high levels of uPAR expression observed in the
current study, during CNS inﬂammation induced by
three distinct challenges (chronic neurodegeneration,
acute neurotoxicity, and acute non-neurotoxic LPS), can
perhaps explain the frequently reported elevations of
suPAR in the CSF of patients with HIV dementia and
other CNS conditions (Cinque et al., 2004; Garcia-Monco
et al., 2002; Sporer et al., 2005; Winkler et al., 2002).
Conversely, neither stroke nor demyelinating diseases
such as MS or Guillian–Barre syndrome resulted in
elevated CSF suPAR despite comprising signiﬁcant
inﬂammatory components (Garcia-Monco et al., 2002). It
seems likely that release of suPAR into the CSF is
directly related to increased CNS inﬂammation as we
observed considerable diffuse staining, that was not cell-
associated, in the parenchyma in addition to microglial
labeling. This would suggest that uPAR is unlikely to
have speciﬁc diagnostic utility for any particular CNS
condition but is likely to be a reliable indicator of cur-
rent CNS inﬂammation. It would appear that many
types of inﬂammation result in shedding of suPAR from
the microglial cell surface in the brain; however, other
factors, currently unknown, may determine uPAR’s
escape to the CSF. Likewise, ﬁndings that cell-surface
levels of uPAR are controlled by endocytosis and recy-
cling (Cortese et al., 2008) should be replicated in micro-
glia, although this would be more easily addressed using
in vitro approaches.
uPA or tPA?
Tissue plasminogen activator (tPA) is constitutively
active in the rodent brain (Sappino et al., 1993) and con-
tributes to the neurotoxicity of kainic acid in rodent
studies (Tsirka et al., 1995, 1997) and, in this regard,
our ﬁnding that tPA rather than uPA is upregulated
after kainate challenge is consistent with the consensus
view of kainate-induced microglial expression of neuro-
toxic tPA. Nonetheless, there is clear evidence that uPA
rather than tPA is the key plasminogen activator in cer-
ebral ischemia in mice, rats, and humans (Cinelli et al.,
2001; Hosomi et al., 2001; Rosenberg et al., 1996), and it
has recently been described as coexpressed with uPA in
brains of HIV patients with opportunistic cerebral infec-
tions (Nebuloni et al., 2008). So, what governs whether
either or both plasminogen activators are switched on
during inﬂammation? It is well described that uPA is
robustly upregulated by macrophage CSF-1 (Stacey
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GLIAet al., 1995), and we have found evidence for increased
transcription of CSF-1 in the ME7 prion disease model
(unpublished observations). In addition, both tPA and
uPA have been described to be differentially regulated
in multiple cell types by IL-1a/b, TNFa, TGFb1, and
prostaglandin E2 (Allan and Martin, 1995; Falcone
et al., 1993, 1995; Gerritsen et al., 1993; So et al., 1992;
Zhang et al., 1996). All these mediators are produced by
intracerebral LPS challenges (Boche et al., 2003), but
TGFb1 and PGE2 would appear to dominate in
ME7-induced prion disease (Cunningham et al., 2002;
Minghetti et al., 2000). Clearly, the regulation of tPA
and uPA in the brain requires considerably more
investigation.
There have been a number of studies published
describing a role for plasminogen activation in prion
disease, but these studies have been focussed on tPA.
Initial studies demonstrated a direct interaction
between plasminogen and disease-associated PrP
(Fischer et al., 2000; Maissen et al., 2001), and subse-
quent in vitro studies suggested that PrP
Sc speciﬁcally
activated tPA without effect on uPA (Ellis et al., 2002;
Epple et al., 2004). Despite this, there is evidence that
tPA cannot degrade PrP
Sc (Xanthopoulos et al., 2005).
The role of plasminogen and tPA in prion disease is
further clouded by divergent results when plasminogen
deﬁcient animals (plg2/2) were inoculated with prion
disease: one study reports a very slight protection of
plg2/2 animals (Salmona et al., 2005), while the other
reports that plasminogen deﬁciency prompts earlier
symptoms and death (Xanthopoulos et al., 2005). These
studies are both compromised by the adverse phenotype
of the plasminogen knockout mouse, which shows poor
health, retarded growth, and shortly after inoculation,
becomes runted, listless, and cachectic (Salmona et al.,
2005). With such an adverse phenotype attributing
symptoms and/or death to prion disease rather than
gene deﬁciency become problematic, perhaps reﬂected in
the very large variability observed in the studies of
Xanthopoulos et al. (2005). Our current studies are sug-
gestive of increases in both tPA and uPA, as shown by
partial inhibition by both amiloride and tPA, and by the
presence of both activities in zymographic analysis. In
addition, the increased transcription of uPA is very
prominent in this disease model given its very low
constitutive expression. Whether uPA synthesis is a
response to PrP
Sc deposition, has a role in microglial
migration/phagocytosis in concert with uPAR, or affects
some other aspect of neuroprotection/neurodegeneration
remains unclear but certainly merits further study.
The Inﬂuence of PAI-1
In models of Alzheimer’s disease, both tPA and uPA
have been reported to show increased expression
(Tucker et al., 2000). However, tPA activity has been
shown by in situ zymography to be decreased in AD
models, and its activity is proposed to be controlled by
the substantial increases in PAI-1 (Melchor et al., 2003).
We also observed PAI-1 elevation in prion disease but
despite its probable presence in the soluble assay, we
still observe considerable increases in plasmin activation
(Fig. 3a). This raises an interesting point about PAI-1
expression. In the current studies, we have observed
clear increases in plasmin activity in both ME7- and
KA-treated animals, but decreased activity in LPS-
treated animals. LPS produced the most marked tran-
scriptional increase in PAI-1, suggesting that PAI-1
expression may be the ultimate determinant of in vivo
plasmin activity. IL-1b, TNF-a, and TGFb1 have all
been shown to induce PAI-1 robustly and to bring about
decreased plasminogen activation (Faber-Elman et al.,
1995), and it is well known that LPS i.c. challenges
induce all these cytokines in the mouse brain (Boche
et al., 2003). Because tPA contributes to neuronal death
during excitotoxicity and uPA to ischemic and cytokine-
induced neurotoxicity (Rosenberg et al., 1996; Thornton
et al., 2008) suppression of these activities during LPS
challenges may be one major reason why this robust
inﬂammatory stimulus is not overtly neurotoxic. Like-
wise, the dominance of tPA/uPA over their inhibitors in
prion disease may have a beneﬁcial effect, in clearing
PrP
Sc, or a deleterious effect in causing bystander pro-
teolytic damage. Furthermore, the balance of PAI-1 and
tPA/uPA from a neuroanatomical point of view may be
key in this regard. Preliminary in situ zymography data
suggest that both plasminogen activator activities are
present in the hippocampus (not shown), but consider-
ably more work is required to clarify this. Nonetheless,
speciﬁc targeting of uPA and/or PAI-1 may produce
interesting effects in the ME7 model of prion disease,
irrespective of previous manipulations of tPA.
CONCLUSION
A number of clinical studies have shown that uPAR is
elevated in the CSF of patients with a variety of CNS
degenerative and/or inﬂammatory diseases. These clini-
cal studies have not been matched by similar basic
research efforts to understand the involvement of uPAR
in these inﬂammatory situations. This study suggests
that uPAR may be involved in a very wide variety of
inﬂammatory and pathological situations in the brain
and systematic studies of its role and that of uPA may
contribute signiﬁcantly to our understanding of many of
these conditions and to a greater understanding of
microglial biology.
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